Biosimilars Portfolio Expansion

About Fresenius Kabi

Fresenius Kabi, a subsidiary of Fresenius SE, is a global healthcare company with a mission to provide essential medicines and technologies for infusion, transfusion, and clinical nutrition. The company reported over €8.6 billion in revenue in 2025 and is executing a strategic transformation plan, #FutureFresenius, with its REJUVENATE phase aimed at accelerating performance and long-term value creation. Its core strength lies in a vertically integrated model of development, manufacturing, and global supply chain management for a broad portfolio of hospital-centric products.

Therapeutic Areas